| 姜斓.胃苓散加味方联合特利加压素协同治疗肝硬化合并Ⅱ型肝肾综合征的临床研究[J].浙江中西医结合杂志,2020,30(1): |
| 胃苓散加味方联合特利加压素协同治疗肝硬化合并Ⅱ型肝肾综合征的临床研究 |
| Clinical Study of Weiling Powder Modified Prescription Combined with Terlipressin in the Treatment of Hepatocirrhosis Complicated with Type II Hepatorenal Syndrome |
| 投稿时间：2019-06-29 修订日期：2019-11-29 |
| DOI： |
| 中文关键词: 胃苓散加味方 特利加压素 肝硬化 Ⅱ型肝肾综合征 临床疗效 |
| 英文关键词:Weiling Powder Modified Prescription Terlipressin Liver Cirrhosis Type II Hepatorenal Syndrome Clinical Effect |
| 基金项目: |
|
| 摘要点击次数: 665 |
| 全文下载次数: 2 |
| 中文摘要: |
| 目的 探讨胃苓散加味方联合特利加压素协同治疗肝硬化合并Ⅱ型肝肾综合征的临床效果。方法 将我院2016年4月-2019年2月收治的76例肝硬化合并Ⅱ型肝肾综合征患者按随机数字表法分为两组（每组38例）。对照组采取常规治疗并加用静脉滴注特利加压素治疗；观察组在对照组的基础上联合胃苓散加味方，冲服，2次/日，两组均治疗一个月。对比分析患者治疗前、后的肝功能、肾功能和24h尿量，治疗后临床疗效及不良反应发生情况。结果 观察组治疗总有效率高于对照组（94.74% vs 76.32%）（χ2=5.208，P=0.022）；两组治疗前的肌酐（Cr）、尿素氮（BUN）和24h尿量水平比较无明显差异（P>0.05）；两组治疗后肾功能及尿量均有显著改善，且观察组的Cr、BUN水平低于对照组，尿量高于对照组（P<0.05）；两组治疗前的丙氨酸氨基转移酶（ALT）及总胆红素（TBIL）、白蛋白（ALB）、凝血酶原活动度（PTA）水平比较无统计学意义（P>0.05）；两组治疗后肝功能各指标均显著改善，且观察组ALT及TBIL显著低于对照组，ALB、PTA水平明显高于对照组（P<0.05）；观察组不良反应发生率（如痉挛性腹痛、腹泻、血压升高、头痛等）与对照组比较，差异无统计学意义（10.53％vs 7.89％）（χ2=0.157，P=0.692）。结论 胃苓散加味方联合特利加压素协同治疗肝硬化合并Ⅱ型肝肾综合征的临床效果显著，可有效的改善患者肝、肾功能，促进尿量且无明显不良反应，更安全。 |
| 英文摘要: |
| Objective: To investigate the clincal efficacy of Weiling Powder Modified Prescription Combined with Terlipressin in the Treatment of Hepatocirrhosis Complicated with Type II Hepatorenal Syndrome. Methods: 76 patients with cirrhosis complicated with hepatorenal syndrome type II in our hospital from April 2016 to February 2019 were selected as the research objects. They were randomly divided into control group and observation group with 38 cases in each group. The control group was treated with routine treatment and intravenous infusion of terlipressin. The observation group was treated with Weiling powder on the basis of the control group, orally, twice a day. Both groups were followed up after one month of treatment. The liver function, kidney function and 24-hour urine volume before and after treatment, clinical efficacy and adverse reactions were compared and analyzed. Results: The total effective rate of the observation group was higher than that of the control group (94.74% vs 76.32%) (χ2=5.208, P=0.022). There was no significant difference in the levels of creatinine (Cr), urea nitrogen (BUN) and 24-hour urine volume between the two groups before treatment (P>0.05). The renal function and urine volume of the two groups were significantly improved after treatment, and the levels of CR and BUN in the observation group were lower than those in the control group, and the urine volume was higher than that in the control group(P<0.05). The levels of alanine aminotransferase (ALT), total bilirubin (TBIL), albumin (ALB), prothrombin activity (PTA) were not significantly different between the two groups before treatment (P>0.05). The liver function of the two groups were significantly improved after treatment, and the levels of ALT and TBIL in the observation group were significantly lower than those in the control group, while the levels of ALB and PTA in the observation group were significantly higher than those in the control group (P<0.05). The incidence of adverse reactions (such as spastic abdominal pain, diarrhea, elevated blood pressure, headache) in the observation group was not significantly different from that in the control group (10.53% vs 7.89%) (χ2=0.157, P=0.692). Conclusion: Weiling Powder Modified Prescription combined with terlipressin in the treatment of liver cirrhosis combined with type II hepatorenal syndrome has a significant clinical effect, which can effectively improve the liver and kidney function of patients, promote urine volume without obvious adverse reactions, and is safer. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
